道氏技術(300409.SZ):擬推2025年限制性股票激勵計劃
格隆匯1月16日丨道氏技術(300409.SZ)公佈2025年限制性股票激勵計劃(草案),本激勵計劃擬向激勵對象授予的限制性股票總量為670.00萬股,佔本激勵計劃草案公吿前一日公司股本總額688,990,546股的0.97%,無預留權益。本激勵計劃限制性股票的授予價格為10.76元/股。
本激勵計劃授予的激勵對象總人數為6人,為公司公吿本激勵計劃草案時在公司任職的董事、高級管理人員、業務骨幹。
本激勵計劃有效期自限制性股票授予之日起至激勵對象獲授的限制性股票全部歸屬或作廢失效之日止,最長不超過48個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.